Fall River, MA Dacon Corp. has completed an expansion to InvaGen Pharmaceuticals’ manufacturing facility. InvaGen is a subsidiary of Cipla (Chemical Industrial Pharmaceutical Laboratories), a global firm founded in 1935 by Dr. K.A. Hamied, who was inspired by Mahatma Gandhi to make India self-sufficient in healthcare. Most notably, Cipla manufactured the first respiratory inhalers in India, followed by the landmark creation of the first triple HIV cocktail therapy for Doctors without Borders. This reduced AIDS treatment to $1 per day, enabling accessible therapies to underserved populations. Today Cipla’s mission of affordable, high-quality medicines spans a continuum of therapeutic categories. Centered on ‘Caring for Life’, their portfolio encompasses over 1,500 products in 86 countries.

Acquired in 2016 as part of a global initiative, the InvaGen Pharmaceuticals division is responsible for the research, development and manufacturing of vital respiratory medications for pediatric and adult use. This facility expansion is in response to employee and manufacturing growth. The need for accessibility, affordability, and efficiency continues to rise for respiratory medications. Fueled by the increase of asthma, COPD and bronchitis, the inhaler market was valued at $4.6 billion in 2022 and is anticipated to grow to $8 billion by 2030. (According to Global Albuterol Market – Industry Trends and Forecast to 2030, Data Bridge Market Research, https://www.databridgemarketresearch.com/reports/global-albuterol market#:~:text=Data%20Bridge%20Market%20Research%20analyses,indicates%20that%20the%20market%20value.)